<DOC>
	<DOCNO>NCT01519076</DOCNO>
	<brief_summary>This study prospective trial wherein include subject receive experimental magnetically enhanced diffusion therapy . It conduct maximum ten adult male female patient meet inclusion exclusion criterion inform consent obtain . Subjects present emergency department acute ischemic stroke eligible tPA therapy may consider inclusion study .</brief_summary>
	<brief_title>A Safety Evaluation Use Magnetic-guided Iron Particles</brief_title>
	<detailed_description>This study prospective trial wherein include subject receive experimental magnetically enhanced diffusion therapy . It conduct maximum ten adult male female patient meet inclusion exclusion criterion inform consent obtain . Subjects present emergency department acute ischemic stroke eligible tPA therapy may consider inclusion study . Subjects meet eligibility criterion treat Magnetically Enhanced Diffusion ( MED ) concurrently tPA infusion . Perfusion assess use CTA/CTP 2-4 hour upon completion tPA infusion use MRI 24 hour upon completion tPA infusion . Subjects follow 14 day , 30 day 90 day post-treatment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Subject 18 80 year age . Subject moderate large ( NIHSS ≥ 10 ≤24 ) ischemic stroke Subject intracranial arterial occlusion middle cerebral artery ( MCA ) , anterior cerebral artery ( ACA ) , internal carotid artery ( ICA ) , posterior cerebral artery ( PCA ) distal basilar artery confirm CT MR angiography . Subject eligible initiation intravenous tPA within three hour stroke onset , time stroke onset define last time patient witness baseline . Subject know sensitivity iron PEG product . Subject recently ( within 30 day ) receive iron replacement therapy . Subject know suspect liver function abnormality . Subject know suspect severe renal impairment . Subject highdensity lesion baseline CT scan consistent hemorrhage degree . Subject significant mass baseline CT consistent midline shift . Subject large ( great onethird middle cerebral artery ) region clear hypodensity baseline CT scan . Subject evidence intraparenchymal tumor baseline CT scan . Subject experience seizure onset stroke . Subject know hemosiderosis hemochromatosis . Subject implantable cardioverter defibrillator , pacemaker , neurostimulator device incompatible MRI . Subject history stroke within last three month . Subject previous exist intracranial hemorrhage , neoplasm , subarachnoid hemorrhage arteriovenous malformation . Subject experience active recent ( within 30 day ) hemorrhage . Subject systolic blood pressure &gt; 185 mmHg diastolic &gt; 110 mmHg . Subject presume septic embolus suspicion bacterial endocarditis . Subject presume pericarditis include pericarditis acute myocardial infarction . Subject suspect aortic dissection . Subject recently ( within 30 day ) undergo surgery biopsy parenchymal organ . Subject recently ( within 30 day ) experience trauma internal injury ulcerative wound . Subject recently ( within 90 day ) experience severe head trauma loss consciousness . Subject know hereditary acquire hemorrhage diathesis , coagulation factor deficiency , oral anticoagulant therapy INR &gt; 1.7 institutionally equivalent prothrombin time . Subject glucose level &lt; 50 mg/dl &gt; 400 mg/dl , platelet count less 100,000 , Hct level less 25 . Subject take dabigatran within last 48 hour new anticoagulant monitor traditional . Subject require hemodialysis peritoneal dialysis , contraindication angiogram . Subject prolong partial thromboplastin time ( PTT ) ( case heparin direct thrombin inhibitor administer within 48 hour ) . Subject recent ( within 7 day ) lumbar puncture arterial puncture noncompressible site . Subject preexist neurological psychiatric disease would confound evaluation . Subject pregnant , nursing intend become pregnant trial period . Subject currently enrol potentially confound research . Subject condition , discretion investigator , would preclude participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stroke</keyword>
</DOC>